Quince Therapeutics QNCX 深 滬
等待開盤 09-24 09:30:00 美东时间
30.15
-1.200
-3.83%
華盛通- 最 高31.01
- 今 開31.01
- 成交量 7589股
- 最 低 29.0251
- 昨 收 31.35
- 總市值 3066.44万
- 52周最高 909.98
- 市盈率 靜 --
- 換手率 0.75%
- 52周最低 15.80
- 委 比 33.33%
- 總股本 101.71万
- 歷史最高 24396.00
- 量 比 0.26
- 振 幅 6.33%
- 歷史最低 16.00
- 每 手 1
- 風險率 253.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Quince Therapeutics Divests Italian Subsidiary, Refocuses Strategy
Quince Therapeutics ( ($QNCX) ) has issued an announcement. On September 8, 202...
09-15 05:45
Quince Therapeutics Faces Nasdaq Listing Compliance Challenges
An announcement from Quince Therapeutics ( ($QNCX) ) is now available. On Augus...
09-04 20:59
Quince Therapeutics Announces Planned Presidential Leadership Transition
Quince Therapeutics ( ($QNCX) ) has shared an update. Quince Therapeutics, Inc....
08-28 05:02
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.
08-18 18:59
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share from the same period last year.
08-14 20:19
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Quince Therapeutics acquired Orphai Therapeutics, adding LAM-001, an inhaled rapamycin formulation for treating pulmonary diseases, to its pipeline. The company secured $115 million in financing, with potential for an additional $83 million, and reported a cash position of $116 million as of June 2026, sufficient to fund operations through 2028. LAM-001 Phase 2b data in PH-ILD is expected in Q1 2028, while Phase 2 data in BOS is anticipated in Q1...
08-14 12:00
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
